Lisa Hopcroft

2.4k total citations
23 papers, 814 citations indexed

About

Lisa Hopcroft is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Lisa Hopcroft has authored 23 papers receiving a total of 814 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 8 papers in Genetics and 6 papers in Molecular Biology. Recurrent topics in Lisa Hopcroft's work include Chronic Myeloid Leukemia Treatments (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Acute Myeloid Leukemia Research (4 papers). Lisa Hopcroft is often cited by papers focused on Chronic Myeloid Leukemia Treatments (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Acute Myeloid Leukemia Research (4 papers). Lisa Hopcroft collaborates with scholars based in United Kingdom, United States and Canada. Lisa Hopcroft's co-authors include Tessa L. Holyoake, Francesca Pellicano, Heather G. Jørgensen, Anthony D. Whetton, Mary T. Scott, Paolo Gallipoli, Ravi Bhatia, Koorosh Korfi, Mhairi Copland and David Vetrie and has published in prestigious journals such as Nature, Nucleic Acids Research and Journal of Clinical Oncology.

In The Last Decade

Lisa Hopcroft

20 papers receiving 808 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa Hopcroft United Kingdom 13 489 342 293 141 117 23 814
Sujiang Zhang China 13 368 0.8× 329 1.0× 223 0.8× 149 1.1× 98 0.8× 62 710
Russell R. Hoover United States 10 352 0.7× 286 0.8× 226 0.8× 152 1.1× 63 0.5× 18 831
Elisabeth Oppliger Leibundgut Switzerland 16 412 0.8× 480 1.4× 311 1.1× 178 1.3× 48 0.4× 38 897
Andrew Kuykendall United States 14 621 1.3× 385 1.1× 512 1.7× 136 1.0× 45 0.4× 174 839
Anand Jillella United States 12 379 0.8× 456 1.3× 113 0.4× 166 1.2× 136 1.2× 48 841
Yi-Hsiang Chen United States 11 338 0.7× 329 1.0× 289 1.0× 109 0.8× 81 0.7× 11 679
Milada S. Vala United States 14 437 0.9× 349 1.0× 177 0.6× 261 1.9× 208 1.8× 20 860
Marina Konopleva United States 13 532 1.1× 365 1.1× 197 0.7× 156 1.1× 52 0.4× 77 739
Daniel H. Wiseman United Kingdom 15 337 0.7× 529 1.5× 104 0.4× 96 0.7× 134 1.1× 46 854
Deborah Fuchs United States 8 606 1.2× 368 1.1× 310 1.1× 101 0.7× 89 0.8× 20 882

Countries citing papers authored by Lisa Hopcroft

Since Specialization
Citations

This map shows the geographic impact of Lisa Hopcroft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Hopcroft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Hopcroft more than expected).

Fields of papers citing papers by Lisa Hopcroft

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Hopcroft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Hopcroft. The network helps show where Lisa Hopcroft may publish in the future.

Co-authorship network of co-authors of Lisa Hopcroft

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Hopcroft. A scholar is included among the top collaborators of Lisa Hopcroft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Hopcroft. Lisa Hopcroft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Symeonides, Stefan N., Duncan Wheatley, Stephen Chan, et al.. (2023). Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment. 199(1). 35–46. 8 indexed citations
2.
3.
Stewart, Grant D., Sarah J. Welsh, Stephan Ursprung, et al.. (2021). NAXIVA: A phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer (RCC) with venous invasion.. Journal of Clinical Oncology. 39(6_suppl). 275–275. 6 indexed citations
4.
Stock, Sarah J., Jade Carruthers, Cheryl Denny, et al.. (2021). Cohort Profile: The COVID-19 in Pregnancy in Scotland (COPS) dynamic cohort of pregnant women to assess effects of viral and vaccine exposures on pregnancy. International Journal of Epidemiology. 51(5). e245–e255. 2 indexed citations
5.
Rooney, Alasdair G, Mairi Mackinnon, Garry A. Anderson, et al.. (2020). INNV-27. BT-LIFE (BRAIN TUMOURS, LIFESTYLE INTERVENTIONS, AND FATIGUE EVALUATION): LESSONS LEARNED FROM RUNNING A NOVEL MULTI-SECTORAL RESEARCH TRIAL. Neuro-Oncology. 22(Supplement_2). ii122–ii122. 1 indexed citations
6.
Pellicano, Francesca, Lisa Hopcroft, Mary T. Scott, et al.. (2018). hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival. Blood. 131(14). 1532–1544. 33 indexed citations
7.
Hopcroft, Lisa, et al.. (2018). Inverse and correlative relationships between TRIBBLES genes indicate non-redundant functions during normal and malignant hemopoiesis. Experimental Hematology. 66. 63–78.e13. 14 indexed citations
8.
Davis, Rachel, et al.. (2017). Effectiveness of a Multidisciplinary Rehabilitation Program Following Shoulder Injury. SHILAP Revista de lepidopterología. 5(3). 3 indexed citations
9.
Tarafdar, Anuradha, Lisa Hopcroft, Paolo Gallipoli, et al.. (2016). CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood. 129(2). 199–208. 56 indexed citations
10.
Scott, Mary T., Koorosh Korfi, Peter Saffrey, et al.. (2016). Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition. Cancer Discovery. 6(11). 1248–1257. 99 indexed citations
11.
Abraham, Sheela A., Lisa Hopcroft, Emma Carrick, et al.. (2016). Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature. 534(7607). 341–346. 165 indexed citations
12.
Sinclair, Amy, Mansi Shah, Mark E. Drotar, et al.. (2016). CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. Blood. 128(3). 371–383. 53 indexed citations
13.
Markowetz, Florian, Florian Markowetz, Carles Pons, et al.. (2015). Systems Genetics. Cambridge University Press eBooks. 4 indexed citations
14.
Pellicano, Francesca, Mary T. Scott, G. Vignir Helgason, et al.. (2014). The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors. Stem Cells. 32(9). 2324–2337. 80 indexed citations
15.
Gallipoli, Paolo, Susan Rhodes, Lisa Hopcroft, et al.. (2014). JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood. 124(9). 1492–1501. 114 indexed citations
16.
Abraham, Sheela A., Lisa Hopcroft, Emma Carrick, et al.. (2013). p53 and c-Myc Are Critical Signaling Hubs That Maintain Chronic Myeloid Leukemia. Blood. 122(21). 1465–1465.
17.
Hopcroft, Lisa, et al.. (2013). “My body’s a 50 year‐old but my brain is definitely an 85 year‐old”: exploring the experiences of men ageing with HIV‐associated neurocognitive challenges. Journal of the International AIDS Society. 16(1). 18506–18506. 24 indexed citations
18.
Izarzugaza, José M. G., et al.. (2011). Characterization of pathogenic germline mutations in human Protein Kinases. BMC Bioinformatics. 12(S4). S1–S1. 16 indexed citations
19.
Hopcroft, Lisa, Martin McBride, Keith Harris, et al.. (2010). Predictive response-relevant clustering of expression data provides insights into disease processes. Nucleic Acids Research. 38(20). 6831–6840. 6 indexed citations
20.
Hopcroft, Lisa, et al.. (2009). Compensated Pathogenic Deviations: Analysis of Structural Effects. Journal of Molecular Biology. 396(1). 19–30. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sujiang Zhang Breakdown of academic impact, for papers by Russell R. Hoover Breakdown of academic impact, for papers by Elisabeth Oppliger Leibundgut Breakdown of academic impact, for papers by Andrew Kuykendall Breakdown of academic impact, for papers by Anand Jillella Breakdown of academic impact, for papers by Yi-Hsiang Chen Breakdown of academic impact, for papers by Milada S. Vala Breakdown of academic impact, for papers by Marina Konopleva Breakdown of academic impact, for papers by Daniel H. Wiseman Breakdown of academic impact, for papers by Deborah Fuchs
Rankless by CCL
2026